Vendredi, 20 Septembre 2019
Dernières nouvelles
Principale » Comprehensive Stock Analysis Of Teva Pharmaceutical Industries Limited (TEVA)

Comprehensive Stock Analysis Of Teva Pharmaceutical Industries Limited (TEVA)

04 Novembre 2017

Many analysts are providing their Estimated Earnings analysis for Teva Pharmaceutical Industries Limited and for the current quarter 22 analysts have projected that the stock could give an Average Earnings estimate of $1.04/share.

A number of other equities analysts have also issued reports on the company. RBC Capital Markets maintained the shares of TEVA in report on Monday, November 14 with "Outperform" rating. Cantor Fitzgerald set a $17.00 price target on Teva Pharmaceutical Industries Limited and gave the company a hold rating in a report on Thursday, October 26th.

While looking at the Stock's Performance, Teva Pharmaceutical Industries Limited now shows a Weekly Performance of -17.97%, where Monthly Performance is -30.16%, Quarterly performance is -45.49%, 6 Months performance is -63.94% and yearly performance percentage is -74.08%. Argus Research maintained the shares of TEVA in report on Tuesday, July 28 with "Buy" rating. Finally, BidaskClub lowered Teva Pharmaceutical Industries Limited from a sell rating to a strong sell rating in a report on Friday, October 13th. Based on 21 analysts polled by TipRanks in the last 3 months, 3 rate a Buy on Teva stock, 15 maintain a Hold, while 3 issue a Sell on the stock. The company presently has a consensus rating of Hold and a consensus price target of $27.21.

Evercore ISI set a $38.00 price target on Teva Pharmaceutical Industries Limited and gave the company a buy rating in a report on Wednesday, October 25th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.03 by ($0.03). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%.

The High Revenue estimate is predicted as 5.76 Million, while the Low Revenue Estimate prediction stands at 5.52 Million. For the next 5 years, Teva Pharmaceutical Industries Limited is expecting Growth of -6.9% per annum, whereas in the past 5 years the growth was -1.21% per annum. The business's quarterly revenue was up.8% compared to the same quarter past year.

Blood-soaked Tiger Shroff goes viral
And now, we have seen the first look of Tiger and it looks even more intense and serious than the previous movie. After their music video "Befikre", the fans are waiting for a full fledged film of them together.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and global trademark & copyright legislation. The rating was maintained by Jefferies with "Hold" on Tuesday, September 12. This represents a $0.34 dividend on an annualized basis and a dividend yield of Infinity.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, November 2nd.

A number of large investors have recently made changes to their positions in TEVA. San Francisco Sentry Investment Group CA purchased a new position in shares of Teva Pharmaceutical Industries Limited in the 2nd quarter valued at $106,000. Teachers Advisors LLC raised its stake in Teva Pharmaceutical Industries Limited by 6.1% during the 1st quarter. Earnings surprises can have a huge impact on a company's stock price.

The Relative Volume of the company is 4.47 and Average Volume (3 months) is 26.27 million. Penserra Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries Limited in the 3rd quarter valued at $129,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in Teva Pharmaceutical Industries Limited during the 1st quarter valued at $16,321,000.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines.

Comprehensive Stock Analysis Of Teva Pharmaceutical Industries Limited (TEVA)